← Leaderboards
Andrew K Godwin
Fox Chase Cancer Center
$21,382,895
Attributed
$28,414,262
Total exposure
23
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,435,360 · 24
By mechanism
P20$23,573,895 · 6
R01$12,541,024 · 5
P30$4,550,060 · 5
P50$3,067,990 · 5
R33$1,207,828 · 1
UL1$334,563 · 1
Top collaborators
- Yong Zeng12 shared
- Steven A. Soper10 shared
- Alan S Yu10 shared
- George Coukos5 shared
- Erica A Golemis5 shared
- Russell J Schilder5 shared
- Michael V. Seiden5 shared
- Margaret Von Mehren5 shared
Most similar at Fox Chase Cancer Center
Same institution · by research overlap
- Russell J Schilder$1,004,899
- Mary Beryl Daly$11,073,226
- Margaret Von Mehren$5,005,730
Others in their field
Top investigators on “Programs”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,641,009,751
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Lawrence Corey · Fred Hutchinson Cancer Center$730,186,538
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$609,313,548
Research focus
ProgramsMalignant NeoplasmsMolecularBaseDiagnosisSamplingFundingAreaResearch PersonnelKansasInnovationClinical TrialsDesignPrecision MedicineBiomedical ResearchFutureProteinsTumorCommunitiesUniversitiesFacultyResourcesTissuesInstitution
Grant awards (107)
The Kansas Institute for Precision Medicine$2,279,653
P20 · FY2025 · GM · contact PI
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem$909,675
R01 · FY2025 · CA · contact PI
Administrative Core$659,083
P20 · FY2025 · GM · contact PI
Developmental Funds Core$628,824
P30 · FY2025 · CA · contact PI
TEAMSPORT to Community TEAMSPORT: Validating and Adapting a Precision Oncology Reflex Testing Team Intervention to Reduce Geographic Variation in Cancer Care Delivery$355,978
R01 · FY2025 · CA
Biobanking and Biovalidation Core$238,954
P20 · FY2025 · GM · contact PI
Biospecimen Shared Resource$184,593
P30 · FY2025 · CA · contact PI
The Kansas Institute for Precision Medicine$2,337,371
P20 · FY2024 · GM · contact PI
Administrative Core$676,215
P20 · FY2024 · GM · contact PI
Developmental Funds Core$648,225
P30 · FY2024 · CA · contact PI
TEAMSPORT to Community TEAMSPORT: Validating and Adapting a Precision Oncology Reflex Testing Team Intervention to Reduce Rural Disparities in Cancer Care Delivery$336,835
R01 · FY2024 · CA
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem$298,484
R01 · FY2024 · CA · contact PI
Biobanking and Biovalidation Core$246,588
P20 · FY2024 · GM · contact PI
The Kansas Institute for Precision Medicine - F-MRPS$217,550
P20 · FY2024 · GM · contact PI
Biospecimen Shared Resource$182,912
P30 · FY2024 · CA · contact PI
The Kansas Institute for Precision Medicine$2,241,937
P20 · FY2023 · GM · contact PI
Administrative Core$949,166
P20 · FY2023 · GM · contact PI
Developmental Funds Core$667,250
P30 · FY2023 · CA · contact PI
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem$593,008
R01 · FY2023 · CA · contact PI
TEAMSPORT to Community TEAMSPORT: Validating and Adapting a Precision Oncology Reflex Testing Team Intervention to Reduce Rural Disparities in Cancer Care Delivery$347,471
R01 · FY2023 · CA
Biobanking and Biomarker Validation (BBV) Core$242,033
P20 · FY2023 · GM · contact PI
Biospecimen Shared Resource$181,264
P30 · FY2023 · CA · contact PI
Administrative Core$164,844
P20 · FY2023 · GM · contact PI
The Kansas Institute for Precision Medicine: IsoPlexis IsoSpark$164,844
P20 · FY2023 · GM · contact PI
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem$157,880
R01 · FY2023 · CA · contact PI
The Kansas Institute for Precision Medicine$2,255,026
P20 · FY2022 · GM · contact PI
Administrative Core$825,299
P20 · FY2022 · GM · contact PI
Developmental Funds Core$687,479
P30 · FY2022 · CA · contact PI
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem$626,871
R01 · FY2022 · CA · contact PI
TEAMSPORT to Community TEAMSPORT: Validating and Adapting a Precision Oncology Reflex Testing Team Intervention to Reduce Rural Disparities in Cancer Care Delivery$354,563
R01 · FY2022 · CA
Biobanking and Biomarker Validation (BBV) Core$221,710
P20 · FY2022 · GM · contact PI
The Kansas Institute for Precision Medicine : Zeiss Axioscan 7$209,704
P20 · FY2022 · GM · contact PI
Biospecimen Shared Resource$179,650
P30 · FY2022 · CA · contact PI
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem$160,842
R01 · FY2022 · CA · contact PI
The Kansas Institute for Precision Medicine$2,226,313
P20 · FY2021 · GM · contact PI
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem$655,455
R01 · FY2021 · CA · contact PI
Administrative Core$493,380
P20 · FY2021 · GM · contact PI
Biobanking and Biomarker Validation (BBV) Core$222,126
P20 · FY2021 · GM · contact PI
Biospecimen Shared Resource$152,698
P30 · FY2021 · CA · contact PI
The Kansas Institute for Precision Medicine$2,252,019
P20 · FY2020 · GM · contact PI
Administrative Core$506,301
P20 · FY2020 · GM · contact PI
The Kansas Institute for Precision Medicine$382,500
P20 · FY2020 · GM · contact PI
Biobanking and Biomarker Validation (BBV) Core$225,848
P20 · FY2020 · GM · contact PI
Biospecimen Shared Resource$151,913
P30 · FY2020 · CA · contact PI
The Kansas Institute for Precision Medicine$2,454,181
P20 · FY2019 · GM · contact PI
Targeting Kinesin Family Member 15 for the Treatment of Cancer$553,464
R01 · FY2019 · CA · contact PI
Administrative Core$483,215
P20 · FY2019 · GM · contact PI
Biobanking and Biomarker Validation (BBV) Core$230,064
P20 · FY2019 · GM · contact PI
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer$195,946
R33 · FY2019 · CA
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer$167,971
R33 · FY2019 · CA
Advancing Precision Medicine Research Through Improved Facilities to Support the Development of Well-Annotated Biospecimen Repository$167,971
P20 · FY2019 · GM · contact PI
Biospecimen Shared Resource$151,143
P30 · FY2019 · CA · contact PI
Targeting Kinesin Family Member 15 for the Treatment of Cancer$623,043
R01 · FY2018 · CA · contact PI
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer$380,938
R33 · FY2018 · CA
Biospecimen Shared Resource$158,774
P30 · FY2018 · CA · contact PI
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer$62,875
R33 · FY2018 · CA
Biospecimen Shared Resource$16,668
P30 · FY2018 · CA · contact PI
Targeting Kinesin Family Member 15 for the Treatment of Cancer$641,589
R01 · FY2017 · CA · contact PI
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer$400,098
R33 · FY2017 · CA
Biospecimen Shared Resource$149,646
P30 · FY2017 · CA · contact PI
Biospecimen Shared Resource$16,585
P30 · FY2017 · CA · contact PI
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$309,390
R01 · FY2014 · CA · contact PI
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$107,546
R01 · FY2014 · CA · contact PI
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$84,070
R01 · FY2014 · CA · contact PI
The Molecular Actions of Imatinib Mesylate in GISTs$358,650
R01 · FY2013 · CA · contact PI
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$310,275
P50 · FY2013 · CA · contact PI
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$305,447
R01 · FY2013 · CA · contact PI
Administrative Core$113,106
P50 · FY2013 · CA
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$73,478
R01 · FY2013 · CA · contact PI
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$57,988
R01 · FY2013 · CA · contact PI
The Molecular Actions of Imatinib Mesylate in GISTs$365,276
R01 · FY2012 · CA · contact PI
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$362,225
R01 · FY2012 · CA · contact PI
Drug Repurposing and Rediscovery for Gastrointestinal Stromal Tumors$334,563
UL1 · FY2012 · TR
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$242,445
P50 · FY2012 · CA · contact PI
Administrative Core$51,659
P50 · FY2012 · CA
The Molecular Actions of Imatinib Mesylate in GISTs$370,916
R01 · FY2011 · CA · contact PI
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$366,458
R01 · FY2011 · CA · contact PI
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$323,787
P50 · FY2011 · CA · contact PI
Administrative Core$141,118
P50 · FY2011 · CA
The Molecular Actions of Imatinib Mesylate in GISTs$433,446
R01 · FY2010 · CA · contact PI
Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer$423,060
R01 · FY2010 · CA · contact PI
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$341,238
P50 · FY2010 · CA · contact PI
Administrative Core$148,187
P50 · FY2010 · CA
The Molecular Actions of Imatinib Mesylate in GISTs$423,095
R01 · FY2009 · CA · contact PI
Targeting Signaling Networks Via Novel RNAi Approaches to Improve Therapy for O$275,341
P50 · FY2009 · CA · contact PI
Biosample and Tissue Procurement Core$142,672
P50 · FY2009 · CA · contact PI
Administrative Core$120,056
P50 · FY2009 · CA
The Molecular Actions of Imatinib Mesylate in GISTs$369,590
R01 · FY2008 · CA · contact PI
The Molecular Actions of Imatinib Mesylate in GISTs$372,714
R01 · FY2007 · CA · contact PI
The Molecular Actions of Imatinib Mesylate in GISTs$370,315
R01 · FY2006 · CA · contact PI
The Molecular Actions of Imatinib Mesylate in GISTs$391,541
R01 · FY2005 · CA
The Molecular Actions of Imatinib Mesylate in GISTs$380,661
R01 · FY2004 · CA
Autopure LS$160,000
S10 · FY2003 · RR
CORE--BIOSAMPLE REPOSITORY$196,218
P30 · FY2002 · CA
Core--Genetic susceptibility testing laboratory$165,355
P50 · FY2002 · CA
Biomarkers of ovarian cancer &molecular genetics of HOSE cell transformation$165,355
P50 · FY2002 · CA
CORE--BIOSAMPLE REPOSITORY$196,218
P30 · FY2001 · CA
Core--Genetic susceptibility testing laboratory$165,355
P50 · FY2001 · CA
Biomarkers of ovarian cancer &molecular genetics of HOSE cell transformation$165,355
P50 · FY2001 · CA
CORE--BIOSAMPLE REPOSITORY$0
P30 · FY2001 · CA
CORE--BIOSAMPLE REPOSITORY$0
P30 · FY2001 · CA
Biomarkers of ovarian cancer &molecular genetics of HOSE cell transformation$50,741
P50 · FY2000 · CA
Biomarkers of ovarian cancer &molecular genetics of HOSE cell transformation$50,741
P50 · FY2000 · CA
Core--Genetic susceptibility testing laboratory$47,602
P50 · FY2000 · CA
Core--Genetic susceptibility testing laboratory$47,602
P50 · FY2000 · CA
CORE--BIOSAMPLE REPOSITORY$0
P30 · FY2000 · CA
CORE--BIOSAMPLE REPOSITORY$0
P30 · FY2000 · CA